<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480307</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-401</org_study_id>
    <secondary_id>2019-004822-15</secondary_id>
    <nct_id>NCT04480307</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
  <acronym>ProTEct-MS</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis (RMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Innovation SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeNeuro Innovation SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled Phase IIa clinical study, assessing safety,
      tolerability, pharmacodynamic effects and pharmacokinetics of temelimab, administered at
      three different dose levels (18 mg/kg or 36 mg/kg or 54 mg/kg).

      In this study temelimab is administered subsequently to rituximab therapy, i.e. no
      co-administration of rituximab and temelimab is done in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: adverse event</measure>
    <time_frame>48 weeks</time_frame>
    <description>To determine if temelimab treatment is associated with an increase of adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in brain parenchymal volume fraction at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in magnetization transfer (MTR) in periventricular NAWM at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in thalamic volume fraction at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in magnetization transfer (MTR) in cortex at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in T1 and T2 lesion volume at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>temelimab 18 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>temelimab 36 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>temelimab 54 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temelimab 18 mg/kg</intervention_name>
    <description>temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).</description>
    <arm_group_label>temelimab 18 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temelimab 36 mg/kg</intervention_name>
    <description>temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).</description>
    <arm_group_label>temelimab 36 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temelimab 54 mg/kg</intervention_name>
    <description>temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).</description>
    <arm_group_label>temelimab 54 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Current diagnosis of RMS, based on McDonald 2017 criteria

          -  Having received treatment with rituximab, as per local clinical routine for at least
             12 months prior to the Screening Visit

          -  Having received their last dose of rituximab not more than 8 weeks and not less than 4
             weeks before Randomization (Study Day 1)

          -  Having expanded disability status scale (EDSS) 2.5 - 5.5 inclusive at Screening

          -  Present clinical worsening in one or more neurological domains as assessed by EDSS,
             ambulatory function as assessed by 6MWT or T25FW, cognitive functioning as assessed by
             SDMT or increased need of walking aids or pharmacological/procedures for bowel and
             bladder functions over the last year.

        Main Exclusion Criteria:

          -  Current diagnosis of primary progressive MS (PPMS)

          -  Any disease other than MS (e.g. myelitis and /or bilateral optic neuritis) that could
             better explain the patient's signs and symptoms

          -  Usage of any of the following medications prior to the Screening visit:

               -  Any usage of interferon beta, glatiramer acetate, IV immunoglobulin (IVIG),
                  dimethyl fumarate or teriflunomide within 12 months prior to Screening,

               -  Any history of exposure to mitoxantrone, cladribine, alemtuzumab,
                  cyclophosphamide, systemic cytotoxic therapy, total lymphoid irradiation, and/or
                  bone marrow transplantation at any time,

               -  Any usage of natalizumab within 24 months prior to Screening,

               -  Any usage of highly potent immune modulating therapy, such as: ocrelizumab,
                  ofatumumab, fingolimod, siponimod, ozanimod or anti-cytokine therapy,
                  plasmapheresis or azathioprine within 12 months prior to Screening,

               -  Any usage of any experimental treatment if not washed out for ≥ 5 half-lives or ≥
                  12 months (whichever is longer), except rituximab which is allowed before the
                  study.

          -  CTCAE Grade 2 or greater lymphopenia

          -  Any major medical or psychiatric disorder that would affect the capacity of the
             patient to fulfill the requirements of the study

          -  History or presence of serious or acute heart disease such as uncontrolled cardiac
             dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or
             uncontrolled congestive heart failure (NYHA class 3 or 4)

          -  Any history of cancer with the exceptions of basal cell carcinoma and/or carcinoma in
             situ of the cervix, and only if successfully treated by complete surgical resection,
             with documented clean margins and any medically unstable condition as determined by
             the investigator

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Leppert, MD</last_name>
    <role>Study Director</role>
    <affiliation>GeNeuro Innovation SAS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Leppert, MD</last_name>
    <phone>0041225524800</phone>
    <email>dl@geneuro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Berthuy</last_name>
    <phone>0041225524800</phone>
    <email>nab@geneuro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Neurology, Academic Specialist Center</name>
      <address>
        <city>Stockholm</city>
        <zip>113 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Piehl</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Forms of Multiple Sclerosis</keyword>
  <keyword>GNbAC1</keyword>
  <keyword>Human Endogenous Retrovirus Type W</keyword>
  <keyword>HERV-W</keyword>
  <keyword>Temelimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

